Given that DDX3 expression is high during active inflammation (Figure 1), these results indicate that targeting DDX3 with RK-33 can reduce the expression levels of several key MMPs involved in inflammation and, as such, provides an indication that targeting DDX3 in IBD patients may be effective at controlling MMP- mediated inflammation. The gene discussed is DDX3X; the disease is inflammatory bowel disease.